Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of AnaptysBio in a research note issued on Tuesday, May 6th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($1.81) per share for the quarter, down from their previous forecast of ($1.58). HC Wainwright currently has a “Neutral” rating and a $22.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q3 2025 earnings at ($1.86) EPS, Q4 2025 earnings at ($2.11) EPS, FY2025 earnings at ($7.02) EPS, FY2026 earnings at ($6.82) EPS, FY2027 earnings at ($9.96) EPS, FY2028 earnings at ($8.90) EPS and FY2029 earnings at ($6.81) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.02. The company had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%.

Other research analysts have also recently issued research reports about the stock. Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Thursday, May 1st. Wolfe Research began coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, Guggenheim raised their price target on AnaptysBio from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.88.

AnaptysBio Stock Up 0.1 %

Shares of AnaptysBio stock opened at $19.59 on Thursday. The business’s fifty day simple moving average is $18.63 and its 200-day simple moving average is $18.71. The firm has a market cap of $579.35 million, a PE ratio of -3.22 and a beta of -0.20. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $41.31.

AnaptysBio declared that its Board of Directors has initiated a share repurchase program on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently modified their holdings of the business. Barclays PLC boosted its holdings in AnaptysBio by 117.4% in the third quarter. Barclays PLC now owns 44,300 shares of the biotechnology company’s stock valued at $1,486,000 after purchasing an additional 23,926 shares during the period. JPMorgan Chase & Co. raised its position in AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after purchasing an additional 22,164 shares in the last quarter. SG Americas Securities LLC raised its position in AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 4,231 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 644 shares during the period. Finally, Jennison Associates LLC grew its position in shares of AnaptysBio by 1.6% during the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock worth $3,563,000 after buying an additional 4,242 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.